These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7542483)

  • 21. Clinical significance of hepatitis B core antibody positivity in HCV-infected and HCV/HIV coinfected individuals.
    Cooper C; Kilby D
    Clin Infect Dis; 2004 May; 38(9):1335-7. PubMed ID: 15127355
    [No Abstract]   [Full Text] [Related]  

  • 22. Detection of chronic liver disease: costs and benefits.
    Quinn PG; Johnston DE
    Gastroenterologist; 1997 Mar; 5(1):58-77. PubMed ID: 9074920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon treatment for chronic viral hepatitis in Australia: is it worth it?
    Farrell GC
    Med J Aust; 1992 Jun; 156(12):873-6. PubMed ID: 1376398
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost effectiveness of interferon in chronic active hepatitis C.
    Sallie R
    Med J Aust; 1994 Jul; 161(2):169-70. PubMed ID: 8080533
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
    Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
    Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of chronic viral hepatitis].
    Sperl J
    Vnitr Lek; 1995 Mar; 41(3):182-4. PubMed ID: 7762176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cold activation of complement for monitoring the response to interferon in patients with chronic hepatitis C.
    Akahane Y; Miyazaki Y; Naitoh S; Takeda K; Tsuda F; Okamoto H; Itoh K; Miyakawa Y; Mayumi M
    Am J Gastroenterol; 1996 Feb; 91(2):319-27. PubMed ID: 8607500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic hepatitis B in india: what is the cost of life?
    Anand AC
    Natl Med J India; 2002; 15(6):317-9. PubMed ID: 12540063
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of chronic viral hepatitis with interferon].
    Rizzetto M; Rosina F
    Recenti Prog Med; 1988 Oct; 79(10):417-9. PubMed ID: 2470123
    [No Abstract]   [Full Text] [Related]  

  • 30. [The goals of therapy].
    Saracco G
    Minerva Gastroenterol Dietol; 1995 Mar; 41(1):77-9. PubMed ID: 7542486
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of chronic hepatitis C: doubts about a cost-effectiveness analysis].
    Bergmann JF
    Gastroenterol Clin Biol; 1997; 21(4):336-8. PubMed ID: 9208001
    [No Abstract]   [Full Text] [Related]  

  • 32. [The treatment of chronic viral hepatitis B/D and acute and chronic viral hepatitis C. The consensus of the German Society for Digestive and Metabolic Diseases].
    Hopf U; Niederau C; Kleber G; Fleig WE
    Z Gastroenterol; 1997 Nov; 35(11):971-86. PubMed ID: 9490556
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of interferon in the treatment of chronic viral hepatitis.
    Gibas AL
    Gastroenterologist; 1993 Jun; 1(2):129-42. PubMed ID: 8049886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon therapy in chronic hepatitis B: more information but clarity eludes.
    Acharya SK; Dasarathy S
    Trop Gastroenterol; 1994; 15(4):177-8. PubMed ID: 7542409
    [No Abstract]   [Full Text] [Related]  

  • 35. [Chronic hepatitis].
    Figueroa Barrios R
    Rev Gastroenterol Peru; 1995; 15 Suppl 1():S77-88. PubMed ID: 8520023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon-alpha in the treatment of chronic viral hepatitis].
    Melman ML
    Rev Gastroenterol Mex; 1994; 59(2 Suppl):46-8. PubMed ID: 8091094
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost effectiveness of interferon in chronic active hepatitis C.
    Turnbull C; Sugano D
    Med J Aust; 1994 Jul; 161(2):169; author reply 170. PubMed ID: 8028544
    [No Abstract]   [Full Text] [Related]  

  • 38. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in the treatment of severe refractory diseases. 2) Viral hepatitis].
    Zeniya M; Toda G
    Nihon Naika Gakkai Zasshi; 1998 Nov; 87(11):2245-9. PubMed ID: 9921209
    [No Abstract]   [Full Text] [Related]  

  • 40. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.